Compare Boston Scientific Corporation (BSX) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Liberty Global Ltd Class C — how do they compare? Boston Scientific Corporation trades at $53.5 (market cap $74.52B), while Liberty Global Ltd Class C trades at $10.2 (market cap $3.54B). The key difference: Boston Scientific Corporation is far larger — about 21.1× Liberty Global Ltd Class C's market cap. Which is the better fit depends on your goals.
| BSX | LBTYK | |
|---|---|---|
Market Cap | $74.52B | $3.54B |
Sector | Health | Technology |
52-Week High | $108.14 | $12.67 |
52-Week Low | $42.63 | $9.59 |
Enterprise Value | $86.60B | $10.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.69, up 0.98% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and revenue growth to $20.07B in 2025, alongside improving net income margins. Analyst sentiment is overwhelmingly positive with 86% buy ratings and a $67.21 consensus price target, though recent news highlights guidance cuts and competitive pressures in key segments like WATCHMAN.
The stock presents a compelling long-term opportunity given robust earnings growth and institutional confidence, but faces near-term risks from execution challenges and market volatility. Upside potential exists if the company stabilizes guidance and leverages new product catalysts, making it attractive for investors with a tolerance for sector-specific headwinds.
Liberty Global (LBTYK) trades at $10.13, up 1.5% on the day, but technical indicators signal a bearish trend. The company reported mixed earnings, with a significant net loss of -$7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for the Ziggo Group spin-off in 2027, a key strategic move.
The outlook is cautiously optimistic, driven by asset monetization and the potential value unlock from the Ziggo Group listing. However, high negative profit margins and substantial losses pose significant risks. Analyst consensus is strongly bullish (69% Buy ratings), seeing upside from sum-of-the-parts valuation, but execution on profitability improvements is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
